Ito S, Takaoka T, Kajimoto Y, Muguruma N, Fukuda T, Okabe T, Horikita M, Hibino S, Hayashi H, Honda H
2nd Department of Internal Medicine, School of Medicine, University of Tokushima, Japan.
Tokushima J Exp Med. 1991 Jun;38(1-2):19-23.
The preventive effect on posttransfusional non-A, non-B hepatitis (PTH) of screening out HCV-Ab positive blood and the prevalence of HCV-Ab-positive donor blood were examined. The incidence of HCV-Ab-positivity in donor blood A was 0.9% and that in donor blood B was 1.35%. The mean ALT and guanase levels were 11.5 +/- 5.8 and 0.58 +/- 0.24 IU/l in HCV-Ab negative blood and 17.3 +/- 7.9 and 0.84 +/- 0.23 IU/l in HCV-Ab-positive blood. Both levels were significantly higher in HCV-Ab-positive blood. These differences were considered to be nonspecific, but there may be some relationship between the levels of ALT and guanase in donor blood and the HCV carrier status. After adoption the screening test for HCV-Ab positive blood, there was no case of a definite diagnosis of PTH, although 4 patients (6.6%) suspected of developing PTH. So, the incidence of PTH was clearly lower than the lowest incidence before adoption of this test. Therefore, we conclude that screening for HCV-Ab in donor blood should be routinely used for prevention of PTH.
研究了筛选丙型肝炎病毒抗体（HCV-Ab）阳性血液对输血后非甲非乙型肝炎（PTH）的预防效果以及HCV-Ab阳性献血者血液的流行情况。献血者血液A中HCV-Ab阳性率为0.9%，献血者血液B中为1.35%。HCV-Ab阴性血液中谷丙转氨酶（ALT）和鸟氨酸氨基甲酰转移酶（guanase）的平均水平分别为11.5±5.8和0.58±0.24 IU/L，HCV-Ab阳性血液中分别为17.3±7.9和0.84±0.23 IU/L。HCV-Ab阳性血液中这两种酶的水平均显著更高。这些差异被认为是非特异性的，但献血者血液中ALT和guanase水平与HCV携带状态之间可能存在某种关系。采用HCV-Ab阳性血液筛查试验后，虽然有4例患者（6.6%）疑似发生PTH，但无确诊为PTH的病例。因此，PTH的发生率明显低于采用该试验前的最低发生率。所以，我们得出结论，应常规筛查献血者血液中的HCV-Ab以预防PTH。
